Skip to content
Fast Company Executive Board

The Fast Company Executive Board is a private, fee-based network of influential leaders, experts, executives, and entrepreneurs who share their insights with our audience.

Biopharma circular systems will move beyond park benches

Recycling innovation keeps critical materials in play.

[Photo: Getty Images]

Profile photo of Jeffrey Whitford

VP, Sustainability & Social Business Innovation · MilliporeSigma

The world only needs so many park benches.

Back in 2015, we launched an industry-first biopharma recycling program to address the new and fast-growing challenge of single-use plastics. At the time, the industry was shifting away from stainless-steel manufacturing systems toward single-use technologies, such as disposable bioreactor bags, filters, and assemblies used to produce life-saving therapies.

Sustainability drove this transition, even if it didn’t look that way at first glance. Traditional stainless-steel systems require large amounts of water and energy to clean and sterilize between batches, which leaves a substantial environmental footprint.

When we ran life-cycle assessments—studies that measure a product’s total environmental impact from creation to disposal—the results were clear. Single-use technologies could reduce overall CO₂ emissions despite introducing more plastic into the system.

Still, that shift created a new problem. If you’re reducing emissions upstream but creating a new waste stream downstream, you’ve just shifted the pressure point.

From breakthrough to baseline

Our initial response was mechanical recycling. In partnership with a waste management company, we developed a process to collect, decontaminate, shred, and repurpose single-use biopharma plastics into secondary products, such as park benches.

At the time, many believed this wasn’t possible. The materials are complex, often contaminated, and regulated. But solving that challenge created important transparency. For the first time, the industry could see what happened to its waste and take responsibility for it.

By 2024, our program had recycled approximately 13,000 tons of single-use material, starting from a mere 57 tons in the first year. That’s meaningful progress by any measure. But progress has a way of raising expectations. Once you prove something is possible, the question becomes: Is it enough?

Turning high-performance materials into low-value products may be better than sending them to a landfill, but it doesn’t fully capture the value of what those materials were designed to do. A park bench is useful, but it doesn’t treat disease, enable innovation, or advance human health.

And that recognition marks the inflection point between recycling and circular systems, which keeps a material in productive use at its highest possible value.

Design for circular systems

That’s where advanced recycling approaches, including chemical recycling, come in. Rather than simply reshaping plastics into lower-value products, these technologies break materials down into their molecular building blocks, which can be reused to create products pure enough for drug manufacturing.

In other words, instead of turning them into something less valuable, such as park benches, we can bring materials back into the same supply chain they came from. This is a fundamentally different proposition for system design rather than waste management.

It’s also not without trade-offs. Chemical recycling carries its own environmental and economic considerations. But it expands what’s possible, especially for materials that are difficult or impossible to recycle mechanically.

Looking further ahead, emerging approaches such as enzymatic recycling (which uses enzymes to break plastics apart) may offer even greater precision and efficiency, though still in early development.

This progression underscores the important truth that sustainability innovation is iterative. Each step builds on the last, informed by data, constrained by reality, and shaped by what technologies can deliver at a given moment in time. Knowing those limits is also what lets us push for the research we’ll need next.

The economics of impact

For circular systems to succeed, the entire ecosystem must work. Biopharma recycling is a chain of interconnected activities: collection, decontamination, sorting, processing, and reintegration. Each step must be viable on its own and aligned with the others.

Ultimately, this is a financial model as much as it is an environmental one. If the economics don’t work—for waste handlers, recyclers, manufacturers, and customers—the system won’t scale.

Trust is equally critical. Materials must meet rigorous quality standards to be reintroduced into highly regulated manufacturing environments. Customers need confidence that recycled inputs will perform exactly as intended, without compromise. Without that assurance, even the most innovative solutions risk becoming theoretical.

Move beyond symbolism

The image of a park bench made from recycled medical plastics makes us feel good, like we did something better. It tells a story of challenging expectations and delivering progress. But it also sets a limit—an endpoint that falls short of what’s truly possible.

The real opportunity is to design systems where waste doesn’t become something else but materials are recovered and returned to their original purpose. That’s the difference between recycling and circularity. Between progress and transformation.

The real question is how quickly we can design recycled park benches out of the equation.


Jeffrey Whitford is the vice president of sustainability and social business innovation, MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany.